Published in FASEB J on May 20, 2004
HIV-1 associated dementia: symptoms and causes. Retrovirology (2006) 1.70
Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. J Exp Med (2005) 1.22
Morphine enhances Tat-induced activation in murine microglia. J Neurovirol (2009) 1.16
HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis. Front Biosci (2008) 1.11
Regulation of neuronal P53 activity by CXCR 4. Mol Cell Neurosci (2005) 1.10
Activation of p38 MAPK is required in monocytic and neuronal cells for HIV glycoprotein 120-induced neurotoxicity. J Immunol (2010) 1.07
Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport. Neurotox Res (2011) 1.03
Role of the transcription factor E2F1 in CXCR4-mediated neurotoxicity and HIV neuropathology. Neurobiol Dis (2006) 0.99
p73 Interacts with human immunodeficiency virus type 1 Tat in astrocytic cells and prevents its acetylation on lysine 28. Mol Cell Biol (2005) 0.96
Critical involvement of the ATM-dependent DNA damage response in the apoptotic demise of HIV-1-elicited syncytia. PLoS One (2008) 0.95
Inhibition of p53 transcriptional activity: a potential target for future development of therapeutic strategies for primary demyelination. J Neurosci (2008) 0.95
Transcription factor p53 influences microglial activation phenotype. Glia (2011) 0.93
Converging roles for sphingolipids and cell stress in the progression of neuro-AIDS. Front Biosci (2008) 0.92
HIV neurotoxicity: potential therapeutic interventions. J Biomed Biotechnol (2006) 0.90
Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol (2009) 0.89
Involvement of the p53 and p73 transcription factors in neuroAIDS. Cell Cycle (2008) 0.87
Methamphetamine abuse, HIV infection, and neurotoxicity. Int J Physiol Pathophysiol Pharmacol (2009) 0.87
The p53 transcription factor modulates microglia behavior through microRNA-dependent regulation of c-Maf. J Immunol (2013) 0.87
Role of p53 in neurodegenerative diseases. Neurodegener Dis (2011) 0.86
Characterization of cell death pathways in human immunodeficiency virus-associated encephalitis. Am J Pathol (2005) 0.85
Mitogen-activated protein kinase p38 in HIV infection and associated brain injury. J Neuroimmune Pharmacol (2011) 0.83
PTEN gene silencing prevents HIV-1 gp120(IIIB)-induced degeneration of striatal neurons. J Neurovirol (2011) 0.81
Emerging roles of p53 in glial cell function in health and disease. Glia (2011) 0.81
A rat model of human immunodeficiency virus 1 encephalopathy using envelope glycoprotein gp120 expression delivered by SV40 vectors. J Neuropathol Exp Neurol (2009) 0.80
Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons. J Biol Chem (2011) 0.79
The Anti-Inflammatory Effects of the Small Molecule Pifithrin-µ on BV2 Microglia. Dev Neurosci (2015) 0.78
The HIV Protein gp120 Alters Mitochondrial Dynamics in Neurons. Neurotox Res (2016) 0.77
Magnetic nanotherapeutics for dysregulated synaptic plasticity during neuroAIDS and drug abuse. Mol Brain (2016) 0.76
Identification of a binding site of the human immunodeficiency virus envelope protein gp120 to neuronal-specific tubulin. J Neurochem (2016) 0.76
Role of Oxidative Stress in HIV-1-Associated Neurocognitive Disorder and Protection by Gene Delivery of Antioxidant Enzymes. Antioxidants (Basel) (2014) 0.76
p53 as a retrovirus-induced oxidative stress modulator. J Gen Virol (2014) 0.75
Fate of microglia during HIV-1 infection: From activation to senescence? Glia (2016) 0.75
ASPP2 Plays a Dual Role in gp120-Induced Autophagy and Apoptosis of Neuroblastoma Cells. Front Neurosci (2017) 0.75
Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia. J Neurochem (2015) 0.75
Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND. Brain Sci (2017) 0.75
Endocytic Trafficking of HIV gp120 is Mediated by Dynamin and Plays a Role in gp120 Neurotoxicity. J Neuroimmune Pharmacol (2017) 0.75
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol (2011) 4.76
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med (2008) 2.78
Femtosecond time-delay X-ray holography. Nature (2007) 2.64
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2010) 2.58
Microglia biology in health and disease. J Neuroimmune Pharmacol (2006) 2.53
The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci (2010) 2.37
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J Immunol (2005) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci (2005) 1.89
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. Free Radic Biol Med (2005) 1.85
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis (2006) 1.82
Ecology of the aging human brain. Arch Neurol (2011) 1.78
Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol (2005) 1.77
Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J Am Geriatr Soc (2009) 1.76
Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol (2009) 1.76
LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol (2006) 1.72
Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking. Ann Neurol (2009) 1.71
TWIST is expressed in human gliomas and promotes invasion. Neoplasia (2005) 1.70
Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport (2003) 1.67
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids (2004) 1.63
Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia (2004) 1.61
Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med (2008) 1.61
The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol (2012) 1.56
Biomarkers: mining the biofluid proteome. Mol Cell Proteomics (2005) 1.55
Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol (2013) 1.52
Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol (2008) 1.52
Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart (2006) 1.51
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One (2011) 1.50
Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J (2005) 1.44
Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol (2006) 1.42
Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia (2005) 1.42
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Infrared spectrum and structure of the adamantane cation: direct evidence for Jahn-Teller distortion. Angew Chem Int Ed Engl (2012) 1.40
Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis (2005) 1.39
Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging (2005) 1.39
The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol (2008) 1.38
Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am J Pathol (2005) 1.38
Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol (2012) 1.37
Microglia in ischemic brain injury. Future Neurol (2010) 1.36
Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J Neurosci (2002) 1.34
Associations between microinfarcts and other macroscopic vascular findings on neuropathologic examination in 2 databases. Alzheimer Dis Assoc Disord (2009) 1.34
Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J (2005) 1.33
Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol (2005) 1.33
Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One (2009) 1.32
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol (2012) 1.32
A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics (2007) 1.31
Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum. J Neurochem (2003) 1.30
Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation (2007) 1.30
Suppression of murine cerebral F2-isoprostanes and F4-neuroprostanes from excitotoxicity and innate immune response in vivo by alpha- or gamma-tocopherol. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.28
Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging (2006) 1.28
Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem (2004) 1.27
The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol (2010) 1.26
Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J Biol Chem (2008) 1.26
P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc Natl Acad Sci U S A (2004) 1.25
A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol (2008) 1.25
Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol (2008) 1.25
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res (2009) 1.24
Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol (2009) 1.24
Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. FASEB J (2006) 1.24
Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med (2010) 1.24
U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.23
Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport (2009) 1.23
Male microchimerism in the human female brain. PLoS One (2012) 1.21
Prostaglandin H(2)-derived adducts of proteins correlate with Alzheimer's disease severity. J Neurochem (2005) 1.21
VAR2CSA domains expressed in Escherichia coli induce cross-reactive antibodies to native protein. J Infect Dis (2008) 1.20
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med (2008) 1.19
p53-dependent cell death signaling in neurons. Neurochem Res (2003) 1.19
Diabetes and insulin in regulation of brain cholesterol metabolism. Cell Metab (2010) 1.19
Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol (2007) 1.19
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo. J Neuroinflammation (2004) 1.15
Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol (2011) 1.15
Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc Natl Acad Sci U S A (2006) 1.15
Global analysis of the cortical neuron proteome. Mol Cell Proteomics (2004) 1.14
Metabolic vulnerability disposes retinal ganglion cell axons to dysfunction in a model of glaucomatous degeneration. J Neurosci (2010) 1.14
Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. J Neurochem (2004) 1.14
Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice. J Neuroinflammation (2006) 1.14
Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol (2013) 1.14
Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr Med Chem (2008) 1.14
Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. J Neurosci (2009) 1.13